By Colin Kellaher Shares of Orphazyme A/S and CytRx Corp. plummeted on Friday after the U.S. Food and Drug Administration said it wouldn't approve a proposed drug for the fatal genetic...
On track for completing enrollment of current Phase IIa trial in Q1 2006 LOS ANGELES, Feb. 13 /PRNewswire-FirstCall/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company engaged in...
- Opportunity for ALS patients to receive continued treatment in open-label extension trial - LOS ANGELES, Jan. 23 /PRNewswire-FirstCall/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical...
CytRx to Present Use of RNAi Technologies to Treat Obesity and Type 2 Diabetes at Metabolic Diseases Forum LOS ANGELES, Sept. 16 /PRNewswire-FirstCall/ -- Mark Tepper, Ph.D., Corporate Vice...
CytRx to Present at the Second International RNAi 2004 Meeting LOS ANGELES, April 28 /PRNewswire-FirstCall/ -- CytRx Corporation announced today that senior CytRx executives will be...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.